You are here: Industry Insights > opaganib

News List

RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19 prnasia
November 30, 2020
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced partnerships with two leading, U.S.-based manufacturers for large-scale manufacturing of opaganib.
RedHill Biopharma's Second COVID-19 Candidate Cleared by FDA for Phase 2/3 Study americanpharmaceuticalreview
November 26, 2020
RedHill Biopharma announced the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for a Phase 2/3 study evaluating orally administered RHB-107 (upamostat) in patients with symptomatic COVID-19 ...
RedHill Biopharma to initiate Phase II/III trial of Covid-19 candidate pharmaceutical-technology
November 19, 2020
RedHill Biopharma is set to start the Phase II/III study evaluating orally administered RHB-107 (upamostat) in patients with symptomatic Covid-19 who do not require hospitalisation.
RedHill Receives Patent Allowance Covering Opaganib, RHB-107 Combination americanpharmaceuticalreview
November 13, 2020
RedHill Biopharma has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application related to the use of two of RedHill’s proprietary investigational compounds, opaganib (Yeliva®, ABC294640) and ..
RedHill Biopharma Ramps-Up Manufacturing of Opaganib contractpharma
October 16, 2020
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to ramp-up manufacturing of opaganib, currently in global Phase 2/3 and ...
Redhill expands manufacturing for COVID-19 candidate pharmatimes
October 16, 2020
Redhill Biopharma has announced partnerships with two specialist pharmaceutical manufacturers in Europe and Canada to increase manufacturing for its COVID-19 candidate opaganib.
Opaganib COVID-19 Study Passes Second Independent Committee Review americanpharmaceuticalreview
October 14, 2020
RedHill Biopharma announced the U.S. Phase 2 study with opaganib (Yeliva®, ABC294640) in patients hospitalized with severe COVID-19 pneumonia has passed its second pre-scheduled safety review by the independent Safety Monitoring Committee (SMC) with a ...
RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2 americanpharmaceuticalreview
September 24, 2020
RedHill Biopharma announced opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes COVID-19, achieving complete blockage of viral replication in an in vitro model of human lung bronchial tissue.
RedHill Biopharma Announces Positive Recommendation from COVID-19 Study americanpharmaceuticalreview
August 31, 2020
RedHill Biopharma announced its U.S. Phase 2 study with opaganib (Yeliva®, ABC294640) in patients hospitalized with severe COVID-19 pneumonia, has successfully passed the first scheduled independent Safety Monitoring Committee (SMC) review.
RedHill Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in UK americanpharmaceuticalreview
July 08, 2020
RedHill Biopharma announced the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the Company’s Clinical Trial Authorization (CTA) application to commence a Phase 2/3 study evaluating opaganib (Yeliva®, ABC294640) ...

Previous page 1 2 3 4 Next page